Diltiazem Hydrochloride Injection Market Report: Trends, Forecast and Competitive Analysis to 2035

Diltiazem Hydrochloride Injection Market

The future of the global diltiazem hydrochloride injection market looks promising with opportunities in the cardiovascular system disease and surgery-related application markets. The global diltiazem hydrochloride injection market is expected to reach an estimated $1010 million by 2035 from $695 million in 2027 with a CAGR of 4.8% from 2027 to 2035. The major drivers for this market are the increasing prevalence of cardiac arrhythmia conditions, the rising use in emergency cardiovascular care, and the growing demand for injectable calcium channel blockers.

• Lucintel forecasts that, within the type category, 10mg/1ml is expected to witness higher growth over the forecast period due to more precise dosing with the 10mg/1ml option.
• Within the application category, cardiovascular system diseases is expected to witness higher growth over the forecast period due to rising cases of cardiovascular diseases.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increased cardiovascular disease burden and access issues in the health care system.

Emerging Trends in Diltiazem Hydrochloride Injection Market

According to Lucintel, the market for diltiazem hydrochloride injection will look different in the years 2025-2027. They attribute this expected shift to the increase in demand for rapid rate control in emergency situations and the need for dependable supply of injectable drugs.

• Supply-chain Diversification: U.S. hospitals signed contracts with alternate suppliers of the injectable in 2025 due to unreliable supply. Pharmaceutical manufacturers have strategically located and twin managed supply of active pharmaceutical ingredients. Since the price difference between alternate suppliers is negligible in the case of time critical cardiovascular care, the focus will be on reliable supply.
• Ready To Use: Demand for ready to use diltiazem hydrochloride injection is increasing due to the variation and risk associated with compounding the injection in an emergency situation. U.S. hospitals will continue to shift their focus on supplies to reduce time it takes to prepare the injection and to minimize the risk of the injection being unsterile.
• Automation and Medication Safety: Controls for the management of intravenous (IV) infusion rates (i.e., bar code infusion administration, intelligent infusion pumps, and electronic automated IV infusion rate control systems) continue to be implemented. The Institute for Safe Medication Practices (ISMP) identifies infusion errors in its annual report on medicine safety. The ISMP report states that in 2025, infusion errors will continue to occur. Other commercially available technologies that facilitate and enhance the control and management of IV infusions will continue to be implemented. Over the next three to five years, products and services that facilitate and enhance digital and oral verification of IV infusion will likely gain market acceptance.
• Evidence-based Acute Care Protocols: Current protocols for the management of atrial fibrillation and atrial flutter increasingly endorse the use of IV infusions of diltiazem. By 2027, similar evidence-based protocols will influence the selection and use of other pharmaceuticals. Products that are uncomplicated, labeled appropriately, of a consistent concentration, and reliable will be selected over generic products.
• Quality Manufacturing of Pharmaceuticals: There will continue to be strict regulation and quality inspections of pharmaceutical manufacturing facilities. This will result in a greater number of recalls of pharmaceuticals. The trend toward strict regulation will reward manufacturers that are able to consistently and reliably produce pharmaceuticals that meet the defined requirements.

Because IV diltiazem is primarily used in the management of cardiac emergencies, this product will continue to be in high demand and available in the marketplace. Over the next several years, the focus will be on the manufacturing quality of pharmaceuticals and how the product integrates with clinical protocols

Recent Developments in the Diltiazem Hydrochloride Injection Market

The market for diltiazem HCl injection is predicted to undergo stagnant growth, mainly due to regulatory changes. Between the years 2025 to 2027, market growth is anticipated from changes in demand by the cardiovascular customer base, together with the introduction of competitor products and procurement activities. As per Lucintel, the key considerations for market participants should be the enhancement of quality and manufacturing processes.

• Market Consolidation: In 2025, the group purchasing organization Vizient reported health systems continued to prioritize the reduction of drug shortages. As a result, manufacturers with surplus capacity and a strong service offerings will be in a competitive position to replace small suppliers.
• Short-term Competitive Manufacturing: Pharmaceutical regulations require manufacturers to enhance production of essential medicinal products. In 2025, the FDA shortage report listed a number of essential medicinal products, thus justifying contingent production.
• Quality Improvement: The FDA issued guidance on the improvement of quality in contract manufacturing of pharmaceutical products. Though the guidance increased the burden on pharmaceutical contract manufacturers, it is expected to reduce the number of deficient products.
• More Broadly, Cardiac-care Services: Diltiazem continues to be widely used in emergency departments to manage atrial fibrillation. It is estimated that more than 6 million people in the U.S. suffer from this condition. Adequate volume is expected to continue to be imposed by patient need, despite preferences for oral options.
• Competition: Several companies have introduced improvements in ready-to-use formulations. In March 2020, numerous companies launched ready-to-use diltiazem. In the absence of specific communications by the companies, it is difficult to assess the level of success of these products. There is a premium on formulations that improve the overall workflow, and decrease the number of steps required to administer the drug, as well as reduce the total cost of the product.

Given the products, and the suppliers of the products, are expected to remain the same over the time period covered, decisions about what to purchase is not expected to be based on clinical innovation. Manufacturers that have flexibility in packaging are expected to be preferred by customers. Reliability, rather than price, is expected to dictate what is purchased.

Strategic Growth Opportunities in the Diltiazem Hydrochloride Injection Market

Between 2024 and 2026 the market for diltiazem hydrochloride injection will grow as hospitals face issues such as challenges in managing cardiovascular admissions and vascular medication stock. Based on Lucintel analysis, demand will be for safe, easy to use, and quickly accessible forms of the drug beyond large tertiary care hospitals.

• Easy To Use Forms: There are a number of potential advantages of using a ready to use ( RTU) form of the drug including decreased preparation and administration error and time. As of January 2025, the U.S. form of the drug was at a concentration of 5 mg/mL. In the next 3 to 5 years, it is likely that hospital pharmacies will want and be able to readily provide emergency pharmaceutical services.
• Outpatient Cardiac Care: Demand for pharmaceutical services outside of the inpatient setting will likely increase. In March 2025, a change in the Medicare order set increased the number of beneficiaries covered from 47 to 66 million. Suppliers of drugs and medical devices that are packaged for easy use and offer clear instructions for use may be well positioned to capture this change.
• Manufacturing Flexibility: In January 2025, the FDA shortage report indicated that several drug makers voluntarily limited production of a number of drug injections. Dual manufacturing may allow drug companies to mitigate supply shortages. Buyers will reward drug companies for supply flexibility.
• Increasing The Scope of Hospital Injectables: Opportunities exist to expand hospital injectable products and services in Southeast Asia, Latin America, and the Middle East. The World Bank's 2025 report forecasted demand for essential medicines and indicated public health funding would continue. This would provide opportunities for injectable products and services requiring cold-chain logistics and local registration.
• Value Added Services: Injectable products and related services could include automation of orders, management of inventory, and other value-added services. Incorporation of barcodes and/or RFID into medical products and other industrial products are anticipated to increase in the medical field in the years approaching 2027. Vendors integrating barcodes/RFID into medical product packaging with positive impact on hospital workflows would likely retain and/or increase their market share.

The difference in price for similar products will decrease, and the focus will be on how products are administered, safety, and service Integration, e.g. how products impact hospital workflows and help achieve their service goals. Products made to be used in hospitals will likely gain market share and preferential listing on hospital formularies. While suppliers charged a premium for their products in the past, the trend may continue in the future.

Diltiazem Hydrochloride Injection Market Drivers and Challenges

Diltiazem hydrochloride injection market is a combination of different factors including the pharmaceutical industry's capability and willingness to produce the drug, the regulatory framework, the health-care system and the demand for the drug. There are various factors that influence the injection market including the practices of health-care professionals, the level of competition among pharmaceutical companies, the quality of the drug, and the types of contracts signed between pharmaceutical companies and health-care institutions. The aforementioned factors will influence market growth and the innovation in the field during the next few years.

The factors responsible for driving this market include :

• Increase in Demand: Rapid control of certain types of cardiac arrhythmias will require the continued use of diltiazem injection. It is expected that the increasing prevalence of cardiovascular diseases and the related emergencies will warrant the continued use of this injectable drug in the health-care system.
• Hospital and Emergency Care Utilization: Various hospital units, including emergency departments, ICUs, ORs, and cardiac units, respond to the needs of patients in a rapidly changing and sometimes unpredictable manner. Intravenous (IV) medications are commonly used in such situations. The standard protocol in various units of a hospital in March 2025, was to employ IV medications to control an abnormal heart rate. The employment of IV medications to control an abnormal heart rate over an oral formulation indicates that an urgent and appropriately timed rapid control of the cardiac condition of the patient is required. Such a situation is expected to persist in the next three to five years.
• Product and Packaging Innovation: Better integration of the principles of design, materials, and improvements in packaging systems have significantly reduced preparation errors and enhanced the ease and speed of medications administration. In February 2025, a 25 mg dose of an injectable medication was the formulation of choice. Of particular significance is the integration of ready-to-use formulations in the packaging systems, along with improved containers and labels. Ready-to-use formulations are particularly suitable to reduce medication errors and the time spent in preparing medications for administration. The same emphasis in product innovations to reduce time and increase workflow in hospitals is expected to continue in the next three to five years.
• Regulatory Quality Support: Requirements related to the sterility and potency of medicinal products as well as their future, long-term, and comparability (percept) stability, extractables a continuity of manufacturing requirements demand high levels of assurance and control over the manufacturing process of medicinal products, including vaccines, biologicals, and advanced therapy medicinal products (ATMPs) in injectable forms. Stringent quality expectations were and will be in place over the next several years. As of April 2025, errors related to contamination and/or dosage concentration of injectable medicinal products placed quality expectations on product manufacture and control. Investing in required quality systems helps build trust of product end users and strengthens the competitiveness of manufacturer's products in the marketplace. In the next 3 to 5 years, implementing quality by design (QbD) and other related strategies by product manufacturers will be important to ensure the trust and satisfaction of the users of medical products.
• Manufacturing and Supply Chain: For injectable medicinal products, including ATMPs, having a reliable source of active pharmaceutical ingredients (APIs) and implementing integrated, automated, and smart systems for processing and managing medicinal products will improve the availability of such products in the market. As of May 2025, the availability of a standard 5 mg/mL strength of a medicinal product facilitated the management of hospital pharmacy stocks. Manufacturers who are able to integrate forward and backward inventory safety stock in their supply chains will be able to respond to variability and disruption in customer (i.e., hospital) demand. In the next 3 to 5 years, the ability to reliably and consistently fulfill customer demand for essential medicinal products will be of key importance to maintain competitiveness.

The challenges facing this market include:

• Supply Disruptions and Shortages: The sterile injectable drug market is subject to disruptions and shortages for many of the same reasons the generic drug market is. Raw material and capacity constraints, contamination, and equipment failures are a few of the many reasons disruptions occur. Continuous shortages can negatively impact patients. Hospitals had to continue to find alternative sources for injectable medicines in 2025 because of shortages. Limited supplier diversity increases risk and gives the customer less bargaining power. In the next five years, the customer will need risk reduction strategies, increased inventory, and manufacturing flexibility. If shortages continue and negatively impact patient care, alternatives should be considered.
• Pricing Pressure and Limited Differentiation: Many of the same buyers and payers put price and margin pressure on the supplier. In 2025, many of the most commonly used injectable medicines offered little to no difference clinically. Pricing and product availability were the determining factors in purchasing. Little to no margin left by payers and buyers of the product encourages manufacturers to forgo product improvement and packaging changes. This puts the product at risk of being unsuitable for use in high risk, high reward situations. Excessive price pressure changes the injectable product market and increases the risk of supply shortages.
• Clinical Safety and Regulatory Complexity: The Intravenous (IV) form of diltiazem has multiple cardiac adverse effects including hypotension and bradycardia, and it is not without consequences in patients with heart failure and other forms of cardiac dysfunction. US labeling is replete with numerous contraindications, warnings, and restrictions. In August 2025, the label stated that the drug should be infused under the close supervision of healthcare personnel. We expect that for the next 3 to 5 years, multiple constraints on the safety of medication will impact the preference and use of this product. The manufacturer that packages and provides instructions for use will have an advantage.

The current and continued reliance on acute intravenous cardiac therapy creates and sustains the need for rapid acting and amenable to injection cardiac medications. We expect further expansion of this market. There are numerous regulatory and manufacturing constraints that will affect how this market is served. Also, the desire and need to enhance the safety of medications will impact this market. We expect the most significant opportunity to improve and positively impact the pharmaceutical supply chain will be to further enhance the resiliency of the supply chain, while also focusing on the needs of the healthcare provider and alleviating supply chain constraints.

List of Diltiazem Hydrochloride Injection Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies diltiazem hydrochloride injection market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the diltiazem hydrochloride injection market companies profiled in this report include-

• Pfizer
• AdvaCare Pharma
• Mylan Pharmaceuticals
• Eugia US
• SagentPharma

Diltiazem Hydrochloride Injection Market by Segment

The study includes a forecast for the global diltiazem hydrochloride injection market by type, application, and region.

Diltiazem Hydrochloride Injection Market by Type [Value ($M) from 2019 to 2035]:

• 10mg/1ml
• 10mg/2ml

Diltiazem Hydrochloride Injection Market by Application [Value ($M) from 2019 to 2035]:

• Cardiovascular System Diseases
• Surgery-Related Applications

Diltiazem Hydrochloride Injection Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Diltiazem Hydrochloride Injection Market

Major players in the diltiazem hydrochloride injection market are focusing on controlling the supply of injectable drugs, establishing local drug manufacturing units and building large-scale production facilities. Large-scale investments by sponsor companies in production of existing drugs are likely to dominate the market till 2027. The pharmaceutical markets of the world would retain procurement resilience and regulatory compliance through 2027. Lucintel's recent analysis has identified ongoing trends, and while these trends affect raw material suppliers, no supplier position is adversely influenced to a great extent. Independent forecasts by Lucintel are not included in this analysis.

• United States: The FDA's focus has been on continuing the national drug shortage program (2025) and implementing the drug supply chain security act (2023). The FDA reported more than 100 active drug shortages in 2025. A focus on drug shortages has created an environment where sponsor companies are encouraged to establish redundant capacity to produce sterile drugs including diltiazem.
• China: 2025 was the eighth year of the national policy that awarded centralized procurement contracts to sell 45 essential medicines at negotiated prices. The Chinese Food and Drug Administration (CFDA) continued to implement policies to increase quality and consistency of ingredients and medicines. Suppliers who can produce diltiazem injection at the lowest cost will be in a favorable position.
• Germany: German implementation of the latest version of the EU pharmaceutical frameworks in 2025, led to the strengthening of pharmaceutical supply pathways and control mechanisms, particularly for critical medicines. This happened at a time when EU manufacturers stepped up their investments for the production of sterile medicines. In May 2025, EU Institutions disclosed a list of about 260 critical medicines, which is expected to influence the production of, and the procurement preferences for, injectable medicines.
• India: The Indian government extended the production-linked incentive (PLI) scheme for the pharmaceutical sector in 2025. The scheme is anticipated to strengthen the domestic production capacity for critical pharmaceutical raw materials and finished dosage forms, including generic diltiazem injection.
• Japan: The Japanese government and manufacturers focused on the consolidation of the quality and production systems for pharmaceuticals in 2025. Other reforms in the pharmaceutical sector facilitated a reduction in the prices of pharmaceuticals. Japan's focus on the supply and costs of pharmaceutical products is expected to sustain the production of pharmaceutical injectables.

Features of the Global Diltiazem Hydrochloride Injection Market

• Market Size Estimates: diltiazem hydrochloride injection market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: diltiazem hydrochloride injection market size by type, application, and region in terms of value ($B).
• Regional Analysis: diltiazem hydrochloride injection market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the diltiazem hydrochloride injection market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the diltiazem hydrochloride injection market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the diltiazem hydrochloride injection market by type (10mg/1ml and 10mg/2ml), application (cardiovascular system diseases and surgery-related applications), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?